We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: ophthalmology
MedXY News
EnglishTag

ophthalmology

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

LISA MRS Formula Outperforms Existing Standards for IOL Calculation in Post-Refractive Surgery Patients, Especially in High Myopia
newsCataract surgeryIOL Calculation

LISA MRS Formula Outperforms Existing Standards for IOL Calculation in Post-Refractive Surgery Patients, Especially in High Myopia

By MedXY|Mar 19, 2026

A new IOL power calculation formula, LISA MRS, demonstrates superior accuracy for cataract patients with prior myopic refractive surgery, significantly outperforming existing formulas in eyes with axial lengths of 28 mm or greater by utiliz

The Persistence of Ophthalmic Scarcity: A 23-Year Longitudinal Analysis of Drug Shortages in the United States
Clinical UpdatesDrug Shortagesophthalmology
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

The Persistence of Ophthalmic Scarcity: A 23-Year Longitudinal Analysis of Drug Shortages in the United States

By MedXY|Mar 20, 2026

This review analyzes ophthalmic drug shortages from 2001 to 2024, revealing that eye medications face longer shortage durations than other drug classes, significantly influenced by patent status and manufacturing transparency.

Impact of Long-Term Intravitreal Anti-VEGF Injections on Cataract Progression and Surgical Outcomes
newsAnti-VEGFBệnh lý võng mạc

Impact of Long-Term Intravitreal Anti-VEGF Injections on Cataract Progression and Surgical Outcomes

By MedXY|Mar 16, 2026

A longitudinal study of 603 patients demonstrates that chronic intravitreal anti-VEGF therapy significantly accelerates cataract development, particularly posterior subcapsular opacities, resulting in an eightfold increased risk for catarac

High-Frequency TENS Shows Promise for Nociplastic Ocular Pain in Randomized Pilot Trial
NeurologyneuromodulationOcular Pain

High-Frequency TENS Shows Promise for Nociplastic Ocular Pain in Randomized Pilot Trial

By MedXY|Mar 13, 2026

This randomized pilot study demonstrates that high-frequency TENS significantly improves specific neuropathic ocular pain symptoms over three months, offering a non-invasive, non-pharmacological alternative for patients with refractory ocul

Beyond the Cornea: Evaluating the Systemic Cardiometabolic Burden in Fuchs’ Endothelial Corneal Dystrophy
Clinical UpdatesFECDmetabolic syndrome

Beyond the Cornea: Evaluating the Systemic Cardiometabolic Burden in Fuchs’ Endothelial Corneal Dystrophy

By MedXY|Mar 13, 2026

Recent data from the NIH All of Us Research Program indicates that Fuchs’ Endothelial Corneal Dystrophy (FECD) is associated with a significantly higher prevalence of cardiometabolic comorbidities, suggesting a systemic component to t

Optimizing Glaucoma Management through Behavioral Intervention: Insights from the SEE Randomized Clinical Trial
Clinical Updatesglaucomaophthalmology

Optimizing Glaucoma Management through Behavioral Intervention: Insights from the SEE Randomized Clinical Trial

By MedXY|Mar 2, 2026

The SEE randomized clinical trial demonstrates that a 6-month personalized coaching program using motivational interviewing significantly improves glaucoma medication adherence and reduces patient distress compared to standard education.

Human-AI Collaboration Enhances Clinical Reasoning in Ophthalmology but Risks Overconfidence and Automation Bias
AIartificial intelligenceophthalmology

Human-AI Collaboration Enhances Clinical Reasoning in Ophthalmology but Risks Overconfidence and Automation Bias

By MedXY|Feb 22, 2026

A crossover study involving 30 ophthalmologists and trainees reveals that while Claude-3.5-Sonnet collaboration improves diagnostic accuracy in complex cases, it also increases confidence in incorrect decisions and fails to reach the perfor

Rapid Fluid Resolution with Faricimab Predicts Long-Term Treatment Durability in nAMD
newsFaricimabnAMD

Rapid Fluid Resolution with Faricimab Predicts Long-Term Treatment Durability in nAMD

By MedXY|Feb 19, 2026

A post hoc analysis of the TENAYA and LUCERNE trials demonstrates that early resolution of retinal fluid by week 12 with faricimab is a significant predictor of achieving extended every-16-week dosing intervals in patients with neovascular

Neuroprotection in NAION: QPI-1007 Fails Primary Endpoint but Shows Promise in Severe Vision Loss
newsNAIONneuroprotection

Neuroprotection in NAION: QPI-1007 Fails Primary Endpoint but Shows Promise in Severe Vision Loss

By MedXY|Feb 4, 2026

This Phase 2/3 trial of QPI-1007 for NAION found that while the primary endpoint was not met for the general population, the siRNA therapy significantly preserved vision in patients with more severe baseline visual impairment.

Tenecteplase Fails to Improve Visual Outcomes in Acute Central Retinal Artery Occlusion: Results from the TenCRAOS Trial
Neurologycentral retinal artery occlusionophthalmology

Tenecteplase Fails to Improve Visual Outcomes in Acute Central Retinal Artery Occlusion: Results from the TenCRAOS Trial

By MedXY|Feb 2, 2026

The TenCRAOS trial demonstrated that intravenous tenecteplase administered within 4.5 hours of acute central retinal artery occlusion does not improve vision recovery compared to aspirin and carries significant safety risks, including fatal

Beyond Total Area: The GAWAIN Index Bridges the Gap Between Retinal Structure and Functional Vision in Geographic Atrophy
newsclinical trialsGeographic Atrophy

Beyond Total Area: The GAWAIN Index Bridges the Gap Between Retinal Structure and Functional Vision in Geographic Atrophy

By MedXY|Jan 30, 2026

Researchers have developed and validated GAWAIN, a novel structural measure for geographic atrophy that weights macular regions by their functional importance. This index correlates significantly better with visual acuity than traditional a

The 22 mm Hg Threshold: Does a Historical Cutoff Still Dictate Modern Glaucoma Management?
newsClinical Decision-Makingglaucoma

The 22 mm Hg Threshold: Does a Historical Cutoff Still Dictate Modern Glaucoma Management?

By MedXY|Jan 17, 2026

A multicenter cohort study of 1.8 million clinic encounters reveals that while clinicians view intraocular pressure as a continuous risk factor, the historical 22 mm Hg cutoff remains a significant psychological trigger for escalating glauc

Foundation Models Narrow the Knowledge Gap in Ophthalmology but Struggle with Images
AIophthalmology

Foundation Models Narrow the Knowledge Gap in Ophthalmology but Struggle with Images

By MedXY|Nov 25, 2025

Contemporary foundation models match experts on text-only ophthalmology exam questions but underperform on image-based items; targeted multimodal training and prospective validation are needed before clinical deployment.

Biodegradable Aflibercept Microsphere‑Hydrogel Shows Long‑Term Ocular Biocompatibility in Rhesus Macaques
newsophthalmology

Biodegradable Aflibercept Microsphere‑Hydrogel Shows Long‑Term Ocular Biocompatibility in Rhesus Macaques

By MedXY|Nov 3, 2025

A biodegradable PLGA microsphere–thermo‑responsive hydrogel delivering aflibercept was well tolerated after single intravitreal injection in 23 rhesus macaques with preserved retinal structure and function up to 24 months.

Cenegermin Eye Drops Show High Healing Rates in Chinese Patients with Moderate–Severe Neurotrophic Keratopathy
newscenegerminChina

Cenegermin Eye Drops Show High Healing Rates in Chinese Patients with Moderate–Severe Neurotrophic Keratopathy

By MedXY|Nov 2, 2025

A prospective phase IV open‑label Chinese study found cenegermin achieved corneal healing in 84.6% of stage 2/3 neurotrophic keratopathy patients at 8 weeks, with durable effects through 56 weeks and an acceptable safety profile.

Prev
2 / 2
12
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities